Restoration of renal function does not correct impairment of uremic HDL properties

Journal of the American Society of Nephrology

Volumn 26, Issue 3, 2015, Pages 565-575

  Kopecky, Chantal ^a   Haidinger, Michael ^a   Birner Grünberger, Ruth ^b   Darnhofer, Barbara ^c   Kaltenecker, Christopher C ^a   Marsche, Gunther ^b   Holzer, Michael ^b   Weichhart, Thomas ^a   Antlanger, Marlies ^a   Kovarik, Johannes J ^a   Werzowa, Johannes ^a   Hecking, Manfred ^a   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c AUSTRIAN CENTRE OF INDUSTRIAL BIOTECHNOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; ARYLDIALKYLPHOSPHATASE; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIGMENT EPITHELIUM DERIVED FACTOR; SERUM AMYLOID A; SURFACTANT PROTEIN B; ULINASTATIN;

ACUTE PHASE RESPONSE; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; ENZYME ACTIVITY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; PROTEINASE INHIBITION; UREMIA; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CHRONIC KIDNEY FAILURE; HOMEOSTASIS; PROTEOMICS;

ADULT; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; HOMEOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEOMICS; UREMIA;

EID: 84924026645     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013111219     Document Type: Article

References (54)

1. Merion RM, Ashby VB, Wolfe RA, Distant DA, Hulbert-Shearon TE, Metzger RA, Ojo AO, Port FK: Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 294: 2726-2733, 2005
2. Meier-Kriesche HU, Ojo AO, Port FK, Arndorfer JA, Cibrik DM, Kaplan B: Survival improvement among patients with end-stage renal disease: Trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 12: 1293-1296, 2001
3. Sunder-Plassmann G, Födinger M, Säemann MD: Cardiovascular disease mortality in kidney transplant recipients: No light at the end of the tunnel? Am J Kidney Dis 59: 754-757, 2012
4. Liefeldt L, Budde K: Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int 23: 1191-1204, 2010
5. Ojo AO: Cardiovascular complications after renal transplantation and their prevention. Transplantation 82: 603-611, 2006
6. Riella LV, Gabardi S, Chandraker A: Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant 12: 1975-1982, 2012
7. Razeghi E, Shafipour M, Ashraf H, Pourmand G: Lipid disturbances before and after renal transplant. Exp Clin Transplant 9: 230-235, 2011
8. Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators: Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 66: 1549-1555, 2004
9. Younas N, Wu CM, Shapiro R, McCauley J, Johnston J, Tan H, Basu A, Schaefer H, Smetanka C, Winkelmayer WC, Unruh M: HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: Statins not associated with improved patient or graft survival. BMC Nephrol 11: 5, 2010
10. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
11. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
12. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377: 2181-2192, 2011
13. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H: Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 378: 1419-1427, 2011
14. Kon V, Ikizler TA, Fazio S: Importance of high-density lipoprotein quality: Evidence from chronic kidney disease. Curr Opin Nephrol Hypertens 22: 259-265, 2013
15. Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T: The versatility of HDL: A crucial anti-inflammatory regulator. Eur J Clin Invest 40: 1131-1143, 2010
16. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH, Stocker R, Säemann MD: Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23: 934-947, 2012
17. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G: Uremia alters HDL composition and function. J Am Soc Nephrol 22: 1631-1641, 2011
18. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117: 746-756, 2007
19. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127-135, 2011
20. Heinecke JW: The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk? Nat Med 18: 1346-1347, 2012
21. Shah AS, Tan L, Long JL, Davidson WS: Proteomic diversity of high density lipoproteins: Our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 54: 2575-2585, 2013
22. Kontush A, Lhomme M, Chapman MJ: Unraveling the complexities of the HDL lipidome. J Lipid Res 54: 2950-2963, 2013
23. Rye KA, Barter PJ: Cardioprotective functions of HDL. J Lipid Res 55: 168-179, 2014
24. Vickers KC, Remaley AT: Functional diversity of HDL cargo [published online ahead of print March 19, 2013]. J Lipid Res doi:10.1194/jlr.R035964
25. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V: Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 60: 2372-2379, 2012
26. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U: Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38: 754-768, 2013
27. Ray K, Wainwright NW, Visser L, Witteman J, Breteler M, Ambegaonkar B, Hofman A, Stricker B, Wareham N, Khaw KT, Sandhu M: Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart 98: 780-785, 2012
28. Tran-Dinh A, Diallo D, Delbosc S, Varela-Perez LM, Dang QB, Lapergue B, Burillo E, Michel JB, Levoye A, Martin-Ventura JL, Meilhac O: HDL and endothelial protection. Br J Pharmacol 169: 493-511, 2013
29. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L: Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 125: 1905-1919, 2012
30. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Lüscher TF, Landmesser U: Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein frompatientswith coronary artery disease: Role of high-density lipoprotein-proteome remodeling. Circulation 127: 891-904, 2013
31. Alwaili K, Bailey D, Awan Z, Bailey SD, Ruel I, Hafiane A, Krimbou L, Laboissiere S, Genest J: The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 1821: 405-415, 2012
32. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST: Proteomic profiling following immunoaffinity capture of high-density lipoprotein: Association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 64: 1828-1837, 2012
33. Legendre C, Canaud G, Martinez F: Factors influencing long-term outcome after kidney transplantation. Transpl Int 27: 19-27, 2014
34. Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J, Tietge UJ, Zidek W, van der Giet M: High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94: 154-162, 2012
35. Nguyen AB, Rohatgi A, Garcia CK, Ayers CR, Das SR, Lakoski SG, Berry JD, Khera A, McGuire DK, de Lemos JA: Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: The Dallas Heart Study. Arterioscler Thromb Vasc Biol 31: 2136-2143, 2011
36. De Pasquale CG, Arnolda LF, Doyle IR, Aylward PE, Chew DP, Bersten AD: Plasma surfactant protein-B: A novel biomarker in chronic heart failure. Circulation 110: 1091-1096, 2004
37. Rakhit DJ, Zhang XH, Leano R, Armstrong KA, Isbel NM, Marwick TH: Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease. Am Heart J 153: 656-664, 2007
38. Riwanto M, Landmesser U: High density lipoproteins and endothelial functions: Mechanistic insights and alterations in cardiovascular disease. J Lipid Res 54: 3227-3243, 2013
39. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58: 342-374, 2006
40. Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM, Pfahler K, Seiler S, Heine GH, März W, Silbernagel G, Fliser D: HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25: 1073-1082, 2014
41. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL: High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med 274: 252-262, 2013
42. Wang F, Zheng J, Ye P, Luo L, Bai Y, Xu R, Sheng L, Xiao T, Wu H: Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. PLoS ONE 8: e79738, 2013
43. Marsche G, Saemann MD, Heinemann A, Holzer M: Inflammation alters HDL composition and function: Implications for HDL-raising therapies. Pharmacol Ther 137: 341-351, 2013
44. Speer T, Zewinger S, Fliser D: Uraemic dyslipidaemia revisited: Role of high-density lipoprotein. Nephrol Dial Transplant 28: 2456-2463, 2013
45. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153: 77-85, 2009
46. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ: The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58: 2068-2075, 2011
47. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Lüscher TF, Landmesser U: Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121: 2693-2708, 2011
48. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M: Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51: 314-324, 2012
49. Khera AV, Rader DJ: Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep 12: 73-81, 2010
50. Rader DJ, Tall AR: The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med 18: 1344-1346, 2012
51. deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51: 2199-2211, 2008
52. Park WD, Larson TS, Griffin MD, Stegall MD: Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function. Transplantation 94: 931-939, 2012
53. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH: Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 46: 2246-2253, 2005
54. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, Resing KA, Ahn NG: Comparison of label-freemethods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 4: 1487-1502, 2005